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ABSTRACT

3

Objective: Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine

4

kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal

5

carcinoma (PPC). The Gynecologic Oncology Group (GOG) conducted a Phase II trial to

6

evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC and

7

explored biomarkers for possible association with clinical outcome.

8

Methods: Eligible women had measurable, recurrent or persistent EOC/PPC and had received

9

one or two prior regimens which must have contained a platinum and a taxane. Patients were

10

treated with 100 mg orally daily of dasatinib continuously until progression of disease or adverse

11

effects prevented further treatment. Primary endpoints were progression-free survival (PFS) ≥6

12

months and response rate. Serial plasma samples were assayed for multiple biomarkers.

13

Circulating free DNA was quantified as were circulating tumor and endothelial cells.

14

Results: Thirty-five (35) patients were enrolled in a two-stage sequential design. Of the 34

15

eligible and evaluable patients, 20.6% (90% confidence interval: 10.1%, 35.2%) had a PFS ≥6

16

months; there were no objective responses. Grade 3-4 toxicities were gastrointestinal (mostly

17

nausea and emesis; n=4), pulmonary (dyspnea and/or pleural effusion; n=4) and pain (n=5),

18

and infrequent instances of anemia, malaise, insomnia, rash, and central nervous system

19

hemorrhage. Lack of clinical activity limited any correlation of biomarkers with outcome.

20

Conclusion: Dasatinib has minimal activity as a single-agent in patients with recurrent

21

EOC/PPC.

22
23

INTRODUCTION
Despite initially high remission rates, at least 75% of women diagnosed with advanced

24

stage epithelial ovarian carcinoma (EOC) will relapse and ultimately die of their disease [1].

25

Treatment of these patients once they develop recurrent disease remains a major problem. The

26

need for new therapeutic strategies is evident. The SRC family of kinases (SFK) is a nine

27

member group of membrane associated non-receptor tyrosine kinases that are involved in a

28

variety of cellular signaling pathways [2]. The SFK is involved in the oncogenesis of numerous

29

tumors including ovarian cancer. SRC regulates many intracellular signaling pathways

30

responsible for various important tumor cell functions such as proliferation, motility and invasion,

31

angiogenesis, and survival. SRC has been found to be overexpressed in a majority of late

32

stage ovarian tumors and cell lines [3].

33

SRC is a component of signaling pathways downstream of many growth factor

34

receptors, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor

35

receptor (VEGFR), and MNNG transforming gene product (c-MET) [4]. Increased resistance to

36

traditional chemotherapy is modulated by SRC through increased activity of RAS and AKT [5].

37

Inhibition of SRC enhanced the activity of cytotoxic agents, including cisplatin, gemcitabine, and

38

paclitaxel through the activation of caspase-3 in pre-clinical models [5-7]. In addition, tumor

39

growth was blunted when human ovarian cancer cells carrying an antisense SRC construct

40

were implanted into mice bearing these xenografts [8].

41

VEGF is an important growth factor for ovarian cancer cells [9]. VEGF was significantly

42

down-regulated by SRC inhibition and microvessel density was reduced [10]. Anti-VEGF

43

therapy has demonstrated activity in patients with recurrent and primary disease [11,12]. VEGF

44

stimulation of its receptor increased tyrosine phosphorylation of focal adhesion kinase, p130

45

CAS and paxillin [13]. Increased activity of these mediators leads to an increased epithelial-to-

5

46

mesenchymal transition (EMT), a crucial step to enhancing the metastatic potential of these

47

cancer cells [14]. SRC is a key intermediate in the EMT process [15,16]. In addition, caveolin-1

48

expression indirectly promotes cell-cell adhesion in ovarian cancer cells [17,18]. SRC interferes

49

with caveolin function also promoting EMT and encouraging tumor spread.

50

Dasatinib is a potent oral inhibitor of breakpoint cluster region-Abelson fusion protein

51

(BCR-ABL), c-KIT, ephrin type-A receptor 2 (EPHA2), c-FMS, and SFK [19,20]. These kinases

52

are implicated in oncogenic process and maintaining the metastatic phenotype of many

53

cancers. Dasatinib’s mechasnism of action depends on itsuccessfully competing for the ATP

54

binding site contained in the kinase domain. The agent is widely approved for chronic

55

myelogenous leukemia and Ph+ acute lymphoblastic leukemia and is now under investigation

56

for treating various solid tumors [21].

57

Based on these observations, the evaluation of dasatinib in patients with recurrent EOC

58

was undertaken by the Gynecologic Oncology Group (GOG). Translational research objectives

59

were included to explore the association between biomarkers and patient outcome. Biomarkers

60

included cell-free DNA (cfDNA), circulating tumor cells (CTCs), circulating endothelial cells

61

(CECs), circulating endothelial precursors (CEPs), and seven plasma biomarkers relevant to

62

dasatinib treatment (EGF and its soluble receptor [sEGFR], VEGF and its soluble receptors

63

[sVEGFR1, sVEGFR2, sVEGFR3], and insulin like growth factor binding protein 2 [IGFBP2]).

6

64
65
66

PATIENTS AND METHODS
Eligibility
Eligible patients had a histologically-confirmed diagnosis of EOC or primary peritoneal

67

carcinoma, measurable disease as defined by Response Evaluation Criteria in Solid Tumors

68

(RECIST) [22], a GOG performance status of 0-2, and adequate bone marrow (absolute

69

neutrophil count ≥1,500/µL, platelet count ≥100,000/µL), renal (serum creatinine ≤1.5 x the

70

upper limit of normal), and hepatic function (total bilirubin ≤1.5 x the upper limit of normal, and

71

transaminases and alkaline phosphatase ≤2.5 x the upper limit of normal). No biomarker based

72

method was used for patient selection. Eligible patients were permitted to have up to two prior

73

cytotoxic regimens, but if a patient had only one prior regimen, she was required to have a

74

platinum-free interval of less than 12 months or to have progressed during or have persistent

75

disease after platinum-based therapy. Prior biological agents were permitted other than those

76

known to inhibit SRC. Patients with prior radiation to more than 25% of marrow bearing areas,

77

therapeutic warfarin treatment, or signs and/or symptoms of bowel obstruction were excluded.

78

Patients provided written informed consent consistent with federal, state, and local institutional

79

review board at each participating GOG institution in accordance with assurances filed with and

80

approved by the Department of Health and Human Services.

81

Treatment Plan and Dose Modifications

82

Dasatinib (Bristol-Myers Squibb, New York, NY) was administered orally at an initial

83

dose of 100 mg once daily until disease progression or adverse effects required interruption,

84

reduction or discontinuation of therapy. Dose level –1 was 70 mg daily and dose level +1 was

85

70 mg twice daily. Although dosing was continuous, a cycle was defined as 28 days. Dasatinib

86

was supplied by Bristol-Myers Squibb, Inc.
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87

Toxicity was graded using the National Cancer Institute Common Toxicity Criteria

88

version 3.0 (NCI-CTCAE v3.0). For first occurrence of febrile neutropenia and/or documented

89

grade 4 neutropenia, dasatinib was held until the absolute neutrophil count (ANC) was grade ≤2

90

then reduced by one dose level. Patients with grade 4 thrombocytopenia had their drug held

91

until grade ≤1 and then were reduced by one dose level. The next cycle of dasatinib did not

92

begin until the ANC was ≥1,500/µl and the platelet count was ≥100,000/µl. Therapy was

93

allowed to be delayed up to a maximum of two weeks. Patients who failed to recover adequate

94

counts within this time were removed from study. Prophylactic use of myeloid growth factors

95

was prohibited. Patients who experienced grade ≥2 non-hematologic toxicity had therapy held

96

until resolution to grade 0-1 up to a maximum of 14 days. Dasatinib was then restarted at 70

97

mg daily. If toxicity recurred to grade 2 or worse, the patient would discontinue study drug.

98

Exceptions to the above modifications included: liver function tests were required to be grade 3

99

or worse toxicity before dose modification was required. There was no dose adjustment for

100

fatigue or alopecia. Doses were reduced for gastrointestinal toxicities only if they could not be

101

controlled with medical management. Fluid retention (pleural effusion and/or ascites) was

102

managed with early initiation of diuretic treatment (furosemide and/or spironolactone. Cavity

103

drainage was performed as clinically indicated. Once a patient’s dose was reduced, no

104

subsequent increases were permitted.

105

Patients with no grade ≥1 toxicities after cycle 1 were escalated one dose level (70 mg

106

twice daily) beginning with cycle 2 of treatment. This dose escalation was included based on

107

early data that solid tumors may require higher doses of dasatinib to achieve clinical activity

108

compared with the doses used to treat patients with CML [23,24].

109

Response Assessment

8

110

Patients were evaluated clinically every four weeks and radiographically every eight

111

weeks. The same evaluation modality was used throughout for each patient on study.

112

Response criteria used were as defined by RECIST [22].

113
114

Translational Research

115

Plasma and whole blood specimens were collected for translational research prior to cycles 1, 2

116

and 3. Detailed methodology and references for isolating and phenotyping CTC and CEC/CEP

117

can be found in the supplemental material [online only]. Methods for determining circulating

118

levels of serum biomarkers and extraction and quantification of total plasma cell-free DNA

119

(cfDNA) are also summarized in the supplemental online material.

120

Statistical Methods

121

We anticipated that the effect of dasatinib might be either cytotoxic or cytostatic.

122

Therefore, the primary endpoint of this study included both objective tumor response and the

123

proportion of patients alive and progression-free after six months PFS-6). Time on study was

124

assessed from date of registration and included all eligible treated patients.

125

The null hypothesis, i.e. an “uninteresting” level of efficacy, was determined from

126

analysis of an historical GOG dataset, based on a similar patient population from clinical trials of

127

study drugs now considered inactive or minimally active. The null hypothesis jointly specified

128

the probability of a patient experiencing a tumor response to be ≤10% and the probability of a

129

patient being alive and free from PFS-6 to be ≤15%. For the purpose of study design, a 20%

130

increase (to 25% for tumor response or to 35% for PFS-6) were considered clinically significant.

131

The two-stage, bivariate, flexible method of Sill and Yothers [25] was used with a goal of limiting

132

patient exposure to inactive agents while restricting the probabilities of type I and type II errors

9

133

to about 10%. If the regimen were to demonstrate sufficient activity in the first stage (with 35

134

patients, this required >5 objective tumor responses or >8 patients with PFS-6), then the study

135

would target a total of 53 patients (cumulatively) in stage 2. Signed-rank tests were used to test

136

changes from baseline in biomarkers, and Wilcoxon rank sum tests were used to compare

137

changes or ratios for patients who had PFS for at least 6 months versus those who did not.

138

Proportional hazards models were used to compare PFS by high (≥ median) versus low

139

(<median) baseline (pre-cycle 1) levels of each parameter; both unadjusted models and models

140

adjusted for age and performance status were examined.

10

141
142
143

RESULTS
Patients and Eligibility
Thirty-five patients were enrolled. One patient was deemed ineligible because

144

inadequate data were available. Patient characteristics are listed in Table 1. A majority of

145

patients (58.8%) received two prior regimens. All patients had a performance status of 0 or 1.

146

Treatment and Response

147

Patients received a median of two cycles (range, 1-12) of protocol therapy. Of the 23

148

patients who received two or more cycles, 15 were escalated to 140 mg of dasatinib daily (70

149

mg bid) and two were reduced to 70 mg daily.

150

There were no responders. Also, only seven patients (20.6%; 90% confidence interval:

151

10.1%, 35.2%) were PFS-6 (Table 2). Therefore, the protocol criteria for continuing to the

152

second stage of accrual were not met. Of the seven patients with PFS ≥6 months, five had two

153

prior treatment regimens while two had received one prior regimen, and all had platinum-

154

resistant disease (<6 months platinum-free interval) Median PFS was 2.1 months (first and third

155

quartiles: 1.8 and 4.9 months). Median overall survival (OS) was 17.7 months (first quartile:

156

10.8 months, third quartile has not been reached; Figure 1).

157

Toxicity

158

The most commonly observed grade 3 toxicities were gastrointestinal (mostly nausea

159

and emesis), pulmonary (dyspnea and/or pleural effusion), and pain (Table 3). There were

160

single cases of grade 3 or 4 anemia, malaise, insomnia, rash, and central nervous system

161

hemorrhage.

162
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163

Translational research

164

Dasatinib related biomarkers

165

Bead-based immunoassays were used to measure circulating levels of seven dasatinib

166

related biomarkers in plasma collected pre-cycles 1 (n=27), 2 (n=23), and 3 (n=15). Fifteen

167

patients submitted samples at all three time points. Median biomarker levels (ng/mL) are

168

presented (Supplemental Table S1). There was a significant increase in the levels of

169

sVEGFR2, sVGEFR3, and IGFBP2 between baseline and pre-cycle three in these patients.

170

There was no association between baseline levels of plasma biomarkers and outcome (PFS

171

and OS) nor between changes in biomarker levels and six-month PFS outcome (data not

172

shown).

173

Circulating cfDNA

174

Total cfDNA from plasma collected pre-cycles 1 (n=28), 2 (n=23), and 3 (n=15) was

175

quantified using a real-time PCR TaqMan Assay and primers directed to β-actin, β-globin, and

176

GAPDH. Median cfDNA totals (GE/mL) are presented (Supplemental Table S2). cfDNA

177

increased from baseline to pre-cycle 2 and decreased between pre-cycle 2 and pre-cycle 3;

178

these changes were not significant. There were no statistically significant associations between

179

baseline measures of cfDNA and outcome (PFS and OS) nor between changes in biomarker

180

levels and six-month PFS outcome (data not shown).

181

Circulating Tumor and Endothelial Cells

182

Whole blood was collected pre-cycles 1 (n=26), 2 (n=21), and 3 (n=12) for CTC and

183

CEC enumeration; CEC VEGFR expression was examined. Twenty-six patients were

184

evaluated for at least one time point; nine patients submitted samples at all three time points.

185

Median biomarker values are presented (Supplemental Table 3). Sixteen patients had >1 CTC

12

186

at one of the three timepoints, with nine patients having >1 at baseline. All patients had CECs

187

(range 14-800) at each timepoint tested. There were no statistically significant associations

188

between baseline CTCs or CECs and outcome (PFS and OS) nor between changes in

189

biomarker levels and six-month PFS outcome (data not shown).

190

CEC VEGFR expression was used to examine whether dasatinib had an effect on

191

endothelial cell activation and whether activation correlates with outcome. We anticipated the

192

percent of VEGFR+ CEC to decrease with a positive anti-angiogenic treatment effect. There

193

was no significant association between baseline CEC VEGFR expression and outcome (PFS

194

and OS) nor between changes in biomarker levels and six-month PFS outcome (data not

195

shown).

196
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197

DISCUSSION

198

Dasatinib was well tolerated but had minimal activity in patients with recurrent ovarian or

199

primary peritoneal carcinoma. With SRC reported to be overexpressed in approximately 90% of

200

ovarian cancers [3], no prescreening was performed to determine eligibility.

201

SRC occupies a strategic position in many cell signaling pathways affecting cell

202

proliferation, growth, and survival [4]. It has an important role in mediating the epithelial-to-

203

mesenchymal transition enhancing the metastatic potential of ovarian cancer cells [15,16].

204

Activated SRC is required for VEGF expression, which has already been shown to be important

205

in ovarian cancer biology and as an important therapeutic target. SRC expression was

206

associated with a drug resistant phenotype and SRC inhibition by transfecting SRC antisense

207

oligonucleotides (or by small molecule inhibitors) reversed drug resistance in preclinical models

208

[6]. Gene expression profiles of ovarian cancer tumors were able to identify with greater than

209

80% accuracy which tumors were likely to be resistant to primary platinum-based therapy

210

[26,27]. These profiles identified expression signatures consistent with activation of SRC which

211

in the future may be used to direct therapeutic strategies.

212

SRC protein expression usually correlated with the degree of SRC pathway

213

deregulation. The more deregulated the pathway, the higher the activated protein expression.

214

Platinum-resistant ovarian cancers have been shown to be more likely to have deregulation of

215

the SRC pathway [5,26]. Kaplan-Meier survival analysis showed that SRC pathway

216

deregulation is associated with a poor survival. Konecny and colleagues tested a panel of 34

217

ovarian cancer cell lines and reported that 71% were highly sensitive to dasatinib [28]. Teoh et

218

al, evaluated the in vitro activity of dasatinib alone and in combination with paclitaxel and

219

carboplatin in ovarian cancer cell lines [29]. Dasatinib demonstrated anti-proliferative activity

220

alone and synergistic activity with the cytotoxic in the cell lines with either SRC pathway

14

221

deregulation and/or high SRC protein expression. Dasatinib did not decrease SRC protein

222

expression, but completely abrogated the activation of SRC in all cell lines tested. These data

223

suggest dasatinib may help prime cells for apoptosis induced by cytotoxic chemotherapy.

224

Investigators at Duke University have conducted a phase I trial of carboplatin, paclitaxel, and

225

dasatinib [NCT00672295], but have yet to report these results.

226

It is not surprising that there was little single agent activity of dasatinib in this trial in light

227

of what has been learned about SRC since the conception and conduct of this trial. Preclinical

228

data support evaluating SRC inhibition in cancers with a predilection for developing metastases

229

to bone based on SRC’s suppression of osteoclast function. A phase II trial of single agent

230

dasatinib investigated its activity in chemotherapy-naïve men with castrate resistant prostate

231

cancer (CRPC). A 43% stable disease rate (SDR) at 12 weeks and a 19 % SDR was

232

observed.(30) This level of activity was very similar to the results of current trial in patients with

233

recurrent ovarian cancer. A biochemical marker of drug activitywas identified with a decline in

234

N-telopeptide, a marker if bone resorption predictive of adverse skeletal events, in men with

235

CRPC treated with dasatinib. Dasatinib has been similarly studied in patients with triple

236

negative breast cancer, Her 2 positive/hormone receptor positive breast cancer with response

237

rates of 4-5%. No or minimal activity also was observed in phase II trials of monotherapy

238

dasatinib in patients with head and neck cancer, glioma and small cell lung cancer (21,31).

239

None of these trials pre-selected patients based on any predictive biomarkers of dasatinib

240

activity. While SRC may be effective (under some circumstances) in suppressing tumor growth,

241

it is not able as monotherapy to cause regression of established tumors. There are

242

compensatory pathways that can bypass blockade of SRC. For example, SRC silencing results

243

in significant increase in FGR levels (another member of the SFK) [32]. Alternatively, activation

244

of JAK may re-establish downstream STAT signaling after inhibition of SFKs [33].
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245

The low activity of dasatinib as a single agent should not preclude evaluation as part of

246

combination regimens, either concomitantly or in sequence prior to chemotherapy if it is borne

247

out that dasatinib can serve a priming function in ovarian cancers with a high degree of SRC

248

pathway deregulation. In this regard, Pathak and Godwin have recently completed in vitro high-

249

throughput screening (HTS) using a siRNA library targeting signaling molecules related to

250

receptor tyrosine kinases in combination with dasatinib. Such screening would identify second-

251

site molecules that can be targeted in combination with SRC inhibition to synergistically improve

252

dasatinib efficacy in patients and to identify a potential gene signature predictive of response to

253

dasatinib therapy (personal communication). The clinical significance of these genes identified

254

through the HTS as being capable of synergizing with SRC inhibition is now being evaluated in

255

blinded tumor biopsy samples from the patients that participated in this trial.

256

Our correlative studies did not show any significance between the biomarkers tested and

257

patient outcome, mainly due to no clinical response on this study. There was a significant

258

increase in the levels of sVEGFR2, sVEGFR3, and IGFBP2 between baseline and pre-cycle 3

259

in the 15 patients submitting samples at all three time points similar to the data reported by

260

Strauss and colleagues [34]. There were no statistically significant changes in the three

261

housekeeping genes from baseline in these patients. The mechanisms of the occurrence of

262

cfDNA in blood under normal and pathological conditions are not yet fully understood. cfDNA

263

might be influenced by apoptosis, necrosis, decreased DNAase activity in circulating cancer

264

cells, as well as clearance by liver/kidney, and modification status of cfDNA. In this study, 16

265

patients had ≥1 CTC at one of the three time points; 9 had ≥1 at baseline. Further investigation

266

of the relationship between cfDNA and circulating CTCs and the predictive value of changes in

267

CTC in patients with ovarian cancer is needed..
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FIGURE LEGEND

Figure 1: Kaplan-Meier plots for overall and progression-free survival.
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